Objective To identify clusters of patients with major depressive disorder (MDD) based on the
baseline 17-item Hamilton Rating Scale for Depression (HAM-D 17) items and to evaluate …

Background: This randomized, open-label, rater-blinded, multicenter study compared
treatment outcomes with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine …

Background: This was a randomized, double-blind, placebo-controlled evaluation of the
efficacy and safety of once-daily venlafaxine extended release (XR) in outpatients with DSM …

Abstract Effects of baseline anxiety on the efficacy of venlafaxine extended release versus
placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in …

Background: Quantifying efficacy and safety differences between drugs is difficult because
rigorous statistical methods to assess benefit and risk simultaneously are lacking. Methods …

Objectives: To determine the relative efficacy and tolerability of venlafaxine in EM vs PM
patients with major depressive disorder (MDD). Method: Data from 4 double-blind, placebo …

Background: Approximately half of patients who are prescribed selective serotonin reuptake
inhibitors (SSRIs) either do not respond to treatment or do not experience a sustained …

The aim of this study was to evaluate the response to venlafaxine in patients with treatment-
resistant depression during an extension phase of an open-label study of venlafaxine. After …

Objective: Evaluate efficacy of standard and higher doses of venlafaxine extended release
(ER) in depressed outpatients who had either not responded to or could not tolerate an …

Venlafaxine inhibits presynaptic reuptake of serotonin (5-hydroxytryptamine; 5-HT) and
noradrenaline (norepinephrine). Venlafaxine extended-release (XR) has been investigated …